Results indicated that replacement of miR-486-5p in lung cancer cell lines induced a decrease in CD133+ CSCs subset in both in vitro and in vivo models through the inhibition of the PI3K/Akt survivability pathway. The gene discussed is AKT1; the disease is lung cancer.